DUBLIN – Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed the acquisition of Viela Bio, Inc. (Nasdaq: VIE) (“Viela”). “The Viela acquisition provides multiple opportunities to drive long-term growth and solidify our future as an innovation-driven biotech company,” said Tim Walbert, chairman, president and chief executive officer, Horizon....
finance News
DUBLIN – Horizon Therapeutics plc (Nasdaq: HZNP), in partnership with MIT Solve, a marketplace for social impact innovation, today announced it has created a first-of-its-kind annual global innovation challenge called The Horizon Prize focused on speeding diagnosis and care for people impacted by rare disease. Each year, The Horizon Prize will...
NEW YORK – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed an agreement with REPROCELL Ltd., a contract research organization (CRO), providing a unique combination of products and services to power translational research, to assess the effect of the HT-003 therapeutic platform on tissue from ulcerative colitis and Crohn’s disease patients. Fresh...
LONDON and NEW YORK – Huma, Europe’s fastest-growing health technology company [1], is partnering with the non-profit patient advocacy group RARE-X, which runs a collaborative patient-powered data collection platform for global data sharing and analysis to accelerate treatments for rare disease. RARE-X’s federated data platform will pair with Huma’s decentralized clinical trials platform, complete...
PARIS & LEIDEN, the Netherlands – Iktos, a company specialized in Artificial Intelligence for new drug design, and Facio Therapies, a drug discovery and development company focused on developing treatments for facioscapulohumeral dystrophy (FSHD), today announced entering a collaboration to apply Iktos’s generative modelling artificial intelligence (AI) technology in one of...
A new collaboration between UW Health, the Waisman Center, and the UW School of Medicine and Public Health aims to discover, diagnose, and ultimately better understand rare genetic diseases. The UW Center for Human Genomics and Precision Medicine at the UW School of Medicine and Public Health recently opened its...
SAN FRANCISCO and SUZHOU, China – Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Ascentage Pharma (6855.HK), today announced a multifaceted strategic collaboration. This collaboration includes: i) the joint commercialization of HQP1351...
Bridgewater, N.J. — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 24 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed’s Compensation Committee and...
NEW YORK, NY — Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today a licensing agreement with Merck KGaA, Darmstadt, Germany for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, currently in development for RAS mutated (RASm) second-line (2L) advanced or metastatic...
SAN FRANCISCO & HONG KONG – With more than 100,000 patients losing sight to Bietti’s Crystalline Dystrophy (BCD) worldwide, Invincible Vision and ReflectionBio® have joined forces to preserve vision of those impacted. Today, ahead of World Rare Disease Day on February 28, the patient-led nonprofit and biotech company are launching...